Download PDF
Int J Angiol 2016; 25(05): e166-e168
DOI: 10.1055/s-0036-1572363
Case Report
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Premature Atherosclerosis and Drug Eluting Stent Restenosis in an Adult with Osteogenesis Imperfecta

Mutlu Gungor
1   Department of Cardiology, Memorial Hospital, Istanbul, Turkey
,
Mustafa Aparci
2   Department of Cardiology, Haydarpasa Training Hospital, Istanbul, Turkey
,
Ali C. Özer
3   Department of Cardiology, Bayındır Hospital, Ankara, Turkey
› Author Affiliations
Further Information

Publication History

Publication Date:
12 February 2016 (online)

    Permissions and Reprints

Abstract

Mild form of osteogenesis imperfecta (OI) may have a normal life span. However, cardiovascular complications including aortic and valvular heart disease, and coronary artery disease may complicate the life period. We presented a patient with mild form of OI and premature coronary atherosclerosis. He had been performed primary percutaneous angioplasty and drug eluting stent implantation to left anterior descending coronary artery osteal lesion. Then he presented with unstable angina pectoris due to the diffuse in-stent restenosis and a highly critical lesion adjacent to previously stented segment. He was suggested coronary artery bypass grafting (CABG), but he preferred coronary angioplasty and was implanted everolimus eluting stent. Control angiography, performed at 9th month, revealed the everolimus eluting stent was satisfactorily patent and the patient was asymptomatic. Numerous genetic defects and histopathological abnormalities of collagen and bone formation that were reported in the etiology of OI may be accounted for premature atherosclerosis in OI. Patients with mild form of OI may present with premature atherosclerosis and acute myocardial infarction. Everolimus eluting stent implantation may be a better choice of drug eluting stent in patients with OI instead of other drug eluting stent or minimally invasive CABG.

Keywords

atherosclerosis - coronary artery - acute coronary syndrome - osteogenesis imperfecta - percutaneous - premature - stent
 

  • References

  • 1 Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A 2014; 164A (6) 1470-1481
    PubMedGoogle Scholar
  • 2 Radunovic Z, Wekre LL, Diep LM, Steine K. Cardiovascular abnormalities in adults with osteogenesis imperfecta. Am Heart J 2011; 161 (3) 523-529
    CrossrefPubMedGoogle Scholar
  • 3 Lamanna A, Fayers T, Clarke S, Parsonage W. Valvular and aortic diseases in osteogenesis imperfecta. Heart Lung Circ 2013; 22 (10) 801-810
    CrossrefPubMedGoogle Scholar
  • 4 McAllion SJ, Paterson CR. Causes of death in osteogenesis imperfecta. J Clin Pathol 1996; 49 (8) 627-630
    CrossrefPubMedGoogle Scholar
  • 5 Migliaccio S, Barbaro G, Fornari R , et al. Impairment of diastolic function in adult patients affected by osteogenesis imperfecta clinically asymptomatic for cardiac disease: casuality or causality?. Int J Cardiol 2009; 131 (2) 200-203
    CrossrefPubMedGoogle Scholar
  • 6 Passmore JM, Walker WE, Fuentes F. Successful aortocoronary bypass in osteogenesis imperfecta. J Am Coll Cardiol 1987; 9 (4) 960-963
    CrossrefPubMedGoogle Scholar
  • 7 Reguillo F, De La Llana R, Castañón J , et al. Osteogenesis imperfecta and coronary artery surgery. A case report. J Cardiovasc Surg (Torino) 1996; 37 (6) 621-622
    PubMedGoogle Scholar
  • 8 Izzat MB, Wan S, Wan IYP, Khaw KS, Yim APC. Ministernotomy for aortic valve replacement in a patient with osteogenesis imperfecta. Ann Thorac Surg 1999; 67 (4) 1171-1173
    CrossrefPubMedGoogle Scholar
  • 9 Eskola MJ, Niemelä KO, Kuusinen PR, Tarkka MR. Coronary artery dissection, combined aortic valve replacement and coronary bypass grafting in osteogenesis imperfecta. Interact Cardiovasc Thorac Surg 2002; 1 (2) 83-85
    CrossrefPubMedGoogle Scholar
  • 10 Forlino A, Marini JC. Osteogenesis imperfecta. Lancet 2015; DOI: 10.1016/S0140-6736(15)00728-X.
    PubMedGoogle Scholar
  • 11 Grange DK, Balfour IC, Chen SC, Wood EG. Familial syndrome of progressive arterial occlusive disease consistent with fibromuscular dysplasia, hypertension, congenital cardiac defects, bone fragility, brachysyndactyly, and learning disabilities. Am J Med Genet 1998; 75 (5) 469-480
    CrossrefPubMedGoogle Scholar
  • 12 Davies MG, Saad WE, Peden EK, Mohiuddin IT, Naoum JJ, Lumsden AB. The long-term outcomes of percutaneous therapy for renal artery fibromuscular dysplasia. J Vasc Surg 2008; 48 (4) 865-871
    CrossrefPubMedGoogle Scholar
  • 13 Cundy T, Horne A, Bolland M, Gamble G, Davidson J. Bone formation markers in adults with mild osteogenesis imperfecta. Clin Chem 2007; 53 (6) 1109-1114
    CrossrefPubMedGoogle Scholar
  • 14 Collin J, Gössl M, Matsuo Y , et al. Osteogenic monocytes within the coronary circulation and their association with plaque vulnerability in patients with early atherosclerosis. Int J Cardiol 2015; 181: 57-64
    CrossrefPubMedGoogle Scholar
  • 15 Zhang H, Wang LJ, Si DL , et al. Correlation between osteocalcin-positive endothelial progenitor cells and spotty calcification in patients with coronary artery disease. Clin Exp Pharmacol Physiol 2015; 42 (7) 734-739
    CrossrefPubMedGoogle Scholar
  • 16 Reyes García R, Rozas Moreno P, Muñoz-Torres M. Osteocalcin and atherosclerosis: a complex relationship. Diabetes Res Clin Pract 2011; 92 (3) 405-406
    CrossrefPubMedGoogle Scholar
  • 17 Sheng L, Cao W, Cha B, Chen Z, Wang F, Liu J. Serum osteocalcin level and its association with carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 2013; 12: 22
    CrossrefPubMedGoogle Scholar
  • 18 Syx D, Guillemyn B, Symoens S , et al. Defective proteolytic processing of fibrillar procollagens and prodecorin due to biallelic BMP1 mutations results in a severe, progressive form of osteogenesis imperfecta. J Bone Miner Res 2015; 30 (8) 1445-1456
    CrossrefPubMedGoogle Scholar
  • 19 Simões Sato AY, Bub GL, Campos AH. BMP-2 and -4 produced by vascular smooth muscle cells from atherosclerotic lesions induce monocyte chemotaxis through direct BMPRII activation. Atherosclerosis 2014; 235 (1) 45-55
    CrossrefPubMedGoogle Scholar